An interdisciplinary team of researchers from The University of Manchester have developed a new graphene-based testing system for disease-related antibodies, initially targeting a kidney disease called membranous nephropathy. The new instrument, based on the principle of a quartz-crystal microbalance (QCM) combined with a graphene-based bio-interface, offers a cheap, fast, simple and sensitive alternative to currently available antibody tests. “Our research has the potential to make antibody testing for various diseases more widely available, at the point of care like GP clinics or care homes, rather than just in specialist testing centres”, said Dr Aravind Vijayaraghavan, from The University of Manchester, who is the lead investigator on this project. The system could also be adapted to test for antibodies to foreign proteins or viral infections, such as COVID-19. “Due to the cheap, fast, simple and sensitive nature of our test, we believe that it is ideal for large-scale deployment in response to pandemics in the UK and elsewhere. In particular, the system would offer significant boost to testing capacity in low- and middle-income countries and remote locations,” added Dr Vijayaraghavan. Collaborative teams The team of collaborative researchers from across The University of Manchester including, the Department of Materials, National Graphene Institute and Faculty of Biology, Medicine and Health have published the results in two open-access papers in the journals ACS Sensors and Carbon. The researchers first studied how biomolecules, like proteins and lipids, adsorb on the surface of different kinds of graphene materials such as graphene oxide and reduced graphene oxide, which are characterised by different degrees of chemical modification of the parent graphene material. Based on this study, they developed a method to form a protein-based layer on graphene, which can then be functionalised with specific receptor molecules for antibodies. These receptors ensure that only the targeted antibody will bind to the graphene surface, and nothing else. While this graphene bio-interface was being developed using a commercial quartz-crystal microbalance system, the authors realised that in order for it to become a widely accessible antibody test system, an alternative read-out instrument was essential. Source
